0001586939-14-000004.txt : 20140505 0001586939-14-000004.hdr.sgml : 20140505 20140505174855 ACCESSION NUMBER: 0001586939-14-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140501 FILED AS OF DATE: 20140505 DATE AS OF CHANGE: 20140505 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FATE THERAPEUTICS INC CENTRAL INDEX KEY: 0001434316 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 3535 GENERAL ATOMICS COURT STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858.875.1803 MAIL ADDRESS: STREET 1: 3535 GENERAL ATOMICS COURT STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Flynn Peter D CENTRAL INDEX KEY: 0001586939 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36076 FILM NUMBER: 14814771 MAIL ADDRESS: STREET 1: C/O FATE THERAPEUTICS, INC. STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2014-05-01 0 0001434316 FATE THERAPEUTICS INC FATE 0001586939 Flynn Peter D C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121 0 1 0 0 See remarks Common Stock 2014-05-01 4 M 0 6925 1.63 A 13656 D Common Stock 2014-05-01 4 M 0 1100 1.63 A 14756 D Common Stock 2014-05-01 4 M 0 422 1.37 A 15178 D Common Stock 2014-05-01 4 S 0 9793 7.0662 D 5385 D Stock Option (right to buy) 1.63 2014-05-01 4 M 0 6925 D 2022-02-08 Common Stock 6925 30816 D Stock Option (right to buy) 1.63 2014-05-01 4 M 0 1100 D 2022-02-08 Common Stock 1100 25300 D Stock Option (right to buy) 1.37 2014-05-01 4 M 0 422 D 2022-07-23 Common Stock 422 19872 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2013. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The shares subject to this option shall vest and become exercisable at the rate of 1/4th of the shares on May 30, 2012 and 1/48th of the shares each month thereafter such that this option is fully exercisable on May 30, 2015. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Not applicable. The shares subject to this option shall vest and become exercisable in 24 equal monthly installments beginning on the date one month after the completion of the Issuer's initial public offering. This option is subject to accelerated vesting upon a change of control of the Issuer after the completion of the Issuer's initial public offering. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 3, 2012 such that this option is fully exercisable on July 3, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Senior Vice President, Early Program Development /s/ Cindy R. Tahl, as Attorney-in-Fact 2014-05-05